Drug intelligence / Profile preview

SAR366234

Development stage: Phase 1
Lead developer: Sanofi
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

SAR366234 is a small molecule drug developed by Sanofi that acts as an agonist of the prostaglandin E2 EP2 receptor. Its primary mechanism of action is to activate the EP2 receptor, which is believed to lower intraocular pressure. The drug was investigated for ophthalmic indications, specifically open-angle glaucoma and ocular hypertension. Clinical development included a completed Phase 1 trial evaluating its safety, tolerability, and pharmacodynamics when administered as topical eye drops in patients with these conditions.

Targets

PTGER2 (Prostaglandin E2 receptor EP2)

Beyond the preview

Go deeper on SAR366234.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR366234.

Explore the full profile